CymaBay Therapeutics reports plans to price public offering of stock

Cowen, Stifel, Roth Capital and National Securities assist with deal

By Devika Patel

Knoxville, Tenn., April 8 - CymaBay Therapeutics, Inc. intends to price a public sale of its common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Cowen and Co. and Stifel are the joint bookrunning managers; Roth Capital Partners and National Securities Corp. are the co-managers.

Proceeds will be used for product development, working capital, capital expenditures and other general corporate purposes.

The Newark, Calif., company develops therapies to treat metabolic and rare diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.